Advanced Unresectable Solid Tumors Clinical Trial
Official title:
A Phase I, Multi-center, Open-label, Single-dose Escalation and Expansion, Dose Escalation and Expansion Combination With Chemotherapy Study Evaluating the Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.
Status | Recruiting |
Enrollment | 152 |
Est. completion date | December 30, 2024 |
Est. primary completion date | July 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent. 2. Advanced Unresectable solid tumors proven by histology 3. At least 1 measurable site of the disease according RECIST 1.1 criteria 4. ECOG performance status (PS) 0-1 5. Life expectancy > 3 months 6. Age = 18 years and =75 years 7. Adequate haematological function; absolute neutrophil count =1.5 x 109/L; white blood cell count =3.0 x 109/L; platelets =100 x 109/L; haemoglobin =9 g/dL. 8. Adequate coagulation function; international normalized ratio ( INR) = 1.5 x upper limit of normal (ULN), or activated partial thromboplastin time (APTT) = 1.5 x ULN. 9. Adequate hepatic function; bilirubin =1.5 x ULN, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) =2.5 x ULN. 10. Adequate renal function; creatinine =1.5 x ULN, or reatinine clearance rate =60 mL/minute calculated. Exclusion Criteria: 1. Previous received or planned to be vaccinated with 2019-nCoV vaccine or other vaccines within 3 months prior to the start of study treatment or during the study or within 3 months after the end of the study; 2. Previous radiotherapy within 4 weeks prior to the start of study treatment. (if palliative radiotherapy was given to bone metastatic side peripherally and the patient recovered from acute toxicity was allowed). 3. Previous anti-tumor therapy within 4 weeks prior to the start of study treatment. 4. Previous major operation within 8 weeks prior to the start of study treatment. 5. Prior severe allergic reaction or intolerance to a monoclonal antibody, including humanised or chimeric antibodies. 6. Symptomatic cerebral metastases. 7. Uncontrolled or severe illness. 8. Known human immunodeficiency virus infection or known symptomatic hepatitis 9. Other clinically significant disease which may have adversely affected the safe delivery of treatment within this study |
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
FutureGen Biopharmaceutical (Beijing) Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events | defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0) | From enrollment until 28+7 days after the last dose | |
Primary | Maximum Tolerated Dose | MTD | 21 days | |
Secondary | Maximum measured plasma concentration of M108 | Cmax | From enrollment until 28 days after the last dose | |
Secondary | Time to maximum plasma concentration of M108 | Tmax | From enrollment until 28 days after the last dose | |
Secondary | Half-life of M108 | T1/2 | From enrollment until 28 days after the last dose | |
Secondary | Immunogenicity profile of M108 | Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies(ADA). | From enrollment until 28 days after the last dose | |
Secondary | Objective Response Rate | ORR | From first dose to disease progression , death or end of study,an average of 1 year | |
Secondary | Progression free survival | PFS | From first dose to disease progression , death or end of study,an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02508441 -
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02428712 -
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
|
Phase 1/Phase 2 |